Fortified Vancomycin
Vancomycin 50 mg/ml · compounded ophthalmic solution
Antibiotic
Approved uses
Serious methicillin-resistant staphylococcal infections (intravenous, non-ocular)
Adults with normal renal function: 2 g IV daily, as 500 mg every 6 hours or 1 g every 12 hours, each given at no more than 10 mg/min or over at least 60 minutes, whichever is longer
OFF-LABELNot in the FDA label for this product
Gram-positive bacterial keratitis, including MRSA
Fortified 25 to 50 mg/mL topically; for central or severe ulcers a loading dose every 5 to 15 minutes, then applications about every hour
Guideline · case series · n=52
Dosing is guideline-based, not trial-based: the AAO Bacterial Keratitis Preferred Practice Pattern lists topical vancomycin 25 to 50 mg/mL for gram-positive cocci and recommends the loading-then-hourly schedule for central or severe keratitis. The best clinical comparison is a retrospective series of 52 culture-proven MRSA keratitis eyes in which fortified vancomycin gave no difference in final visual acuity, treatment duration, or need for surgery versus fourth-generation fluoroquinolones; the authors note the vancomycin-treated ulcers tended to be more severe at presentation, so this is a null result under confounding, not a demonstration of equivalence.
Severe bacterial keratitis, empirically paired with a gram-negative agent
Fortified 5% (50 mg/mL) with fortified gentamicin 1.4%, both given as a loading dose every 5 to 15 minutes then applications about every hour
Prospective cohort · n=49
Prospective cohort of 49 bacterial keratitis patients treated empirically: ulcers healed in 85.7% on gentamicin plus vancomycin, 44.4% on ceftazidime plus vancomycin, and 64.5% on moxifloxacin, a difference that was not statistically significant (p = 0.259). Median time to epithelialization was 21 days with gentamicin plus vancomycin versus 30 days for each of the other two arms (log-rank p = 0.020). Gram-positive isolates in that cohort were 93.3% susceptible to vancomycin, and coagulase-negative staphylococci were 100% susceptible. The authors recommend fortified gentamicin plus vancomycin in severe bacterial keratitis; the frequency of application comes from the AAO practice pattern, not from this cohort.
Contraindications
Known hypersensitivity to vancomycin.
Compounded, no fixed ophthalmic package size, source single-dose vials 500 mg and 1 g, 500 mg vial yields 10 mL at 50 mg/mL
Glycopeptide; bactericidal primarily by inhibiting bacterial cell wall biosynthesis, with added effects on cell membrane permeability and RNA synthesis. No in vitro activity against gram-negative bacilli, mycobacteria, or fungi, so empiric keratitis coverage needs a gram-negative partner drug.
Warnings & Precautions
- Off-label ocular route: The linked label is for intravenous use, so every ocular application on this card is off-label.
- Hemorrhagic occlusive retinal vasculitis: Occurred, including permanent vision loss, after intracameral or intravitreal injection during or after cataract surgery; the drug is not indicated for endophthalmitis prophylaxis and safety by those routes is unestablished.
- Precipitation: Intravitreal injection is not an approved route of administration, and precipitation has been reported after intravitreal injection of vancomycin and ceftazidime for endophthalmitis using different syringes and needles; the precipitates dissolved gradually over two months.
- Infusion Reactions: Rapid bolus administration (e.g., over several minutes) may be associated with exaggerated hypotension, including shock and rarely cardiac arrest. Give it in a diluted solution over a period of not less than 60 minutes; there have been reports that infusion-related events increase in frequency with concomitant anesthetic agents.
- Nephrotoxicity: Systemic vancomycin exposure may result in acute kidney injury (AKI), and the risk of AKI increases as systemic exposure/serum levels increase. Monitor renal function in all patients, especially those with underlying renal impairment or co-morbidities that predispose to renal impairment, and those with concurrent and/or sequential systemic or topical use of other potentially nephrotoxic drugs, such as aminoglycosides, bacitracin, or polymixin B.
- Ototoxicity: Has occurred and may be transient or permanent; it has been reported mostly in patients given excessive doses, with an underlying hearing loss, or on concomitant therapy with another ototoxic agent, such as an aminoglycoside. Use with caution and adjust dosage in renal insufficiency; serial tests of auditory function may be helpful.
- Severe Dermatologic Reactions: Toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and linear IgA bullous dermatosis (LABD) have been reported. Discontinue at the first appearance of signs and symptoms.
- Clostridioides difficile Associated Diarrhea (CDAD): Has been reported with nearly all antibacterial agents, including vancomycin, and may range in severity from mild diarrhea to fatal colitis. CDAD must be considered in all patients who present with diarrhea following antibiotic use; it has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
- Clinically significant serum concentrations: Have been reported in some patients being treated for active C. difficile-induced pseudomembranous colitis after multiple oral doses.
- Superinfection: Prolonged use may result in the overgrowth of nonsusceptible microorganisms; if superinfection occurs during therapy, appropriate measures should be taken.
- Neutropenia: Reversible neutropenia has been reported. Patients on prolonged therapy or receiving concomitant drugs which may cause neutropenia should have periodic monitoring of the leukocyte count.
- Tissue irritation and thrombophlebitis: The drug is irritating to tissue and must be given by a secure IV route; pain, tenderness, and necrosis occur with intramuscular injection or inadvertent extravasation. Thrombophlebitis may occur and can be minimized by giving the drug slowly as a dilute solution (2.5 to 5 g/L) and by rotation of venous access sites.
- Chemical peritonitis: Reports have revealed that intraperitoneal administration during continuous ambulatory peritoneal dialysis (CAPD) has resulted in a syndrome of chemical peritonitis, ranging from cloudy dialysate alone to cloudy dialysate with variable degrees of abdominal pain and fever. Safety and efficacy by the intrathecal or intraperitoneal route have not been established.
- Drug-resistant bacteria: Prescribing in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
- Room-temperature potency loss: In a laboratory potency study, fortified vancomycin 25 mg/mL stayed constant at 4°C but declined by 38% at 24°C on day 14 and by 48% on day 7 and 78% on day 14 at 35°C.
Common Side Effects
With intravenous use, patients may develop anaphylactoid reactions during or soon after rapid infusion, including hypotension, wheezing, dyspnea, urticaria, or pruritus, and rapid infusion may also cause flushing of the upper body. Systemic vancomycin exposure may result in acute kidney injury, and hearing loss, drug fever, nausea, chills, and eosinophilia have been reported. Reversible neutropenia, usually starting 1 week or more after onset of therapy or after a total dosage of more than 25 g, has been reported for several dozen patients. Ocular surface: In a rabbit MRSA keratitis model, vancomycin 50 mg/mL caused epithelial erosion that was worse by a statistically significant margin than in groups treated with topical linezolid 1 mg/mL or 2 mg/mL or isotonic saline.
Pregnancy: Animal reproduction studies have not been conducted, and it is not known whether vancomycin can affect reproduction capacity. A controlled clinical study evaluated the potential ototoxic and nephrotoxic effects of vancomycin on infants when the drug was given to pregnant women for serious staphylococcal infections complicating intravenous drug abuse. Vancomycin was found in cord blood, and no sensorineural hearing loss or nephrotoxicity attributable to vancomycin was noted in the infants. One infant whose mother received vancomycin in the third trimester had conductive hearing loss that was not attributed to vancomycin. Because the number of patients was limited and the drug was given only in the second and third trimesters, it is not known whether it causes fetal harm. Vancomycin should be given to a pregnant woman only if clearly needed.
Lactation: Excreted in human milk. Caution should be exercised when it is given to a nursing woman. Because of the potential for adverse events, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
No ophthalmic data.